CURRENT TREATMENTS FOR AUTOIMMUNE MYOSITIS

There is a lack of targeted treatments available for autoimmune myositis

With current treatment options, disease control can be inconsistent in autoimmune myositis (AIM), with variable responses, worsening signs and symptoms, and repeated treatment changes common in clinical practice.1,2


This leaves an unmet need for immunomodulators that selectively target disease drivers while preserving broader immune function​.3

Current unmet needs

Current Management

Current management of AIM relies heavily on broad immunosuppression and prolonged glucocorticoid exposure, which can reduce inflammation but may not reliably prevent ongoing disease activity, progression, or damage accrual across all muscle and extramuscular manifestations.1,4,5

Blue and white ceramic medicine bottle with anatomical muscle-pattern decoration beside a blue-and-white capsule on a wooden surface.

Important unmet needs for some patients remain, including lack of sustained efficacy, treatment cycling, persistent steroid burden, incomplete control of extramuscular disease, and failure to prevent irreversible damage.4,5

Blue and white ceramic dart board with an arrow hitting the bullseye, displayed on a wooden surface.

These limitations support a move towards targeted therapies informed by the underlying mechanisms of disease, including the autoimmune pathways at the root of AIM pathogenesis.4

An important therapeutic goal is to control pathogenic autoimmunity while preserving protective immunity.3

Continue exploring current treatments for AIM

Current treatments for AIM have several limitations, and few are specifically approved for AIM, highlighting a need for new treatment options.1,4,6 Explore how treatment burden and lack of targeted therapies pose a challenge in treating AIM.4

Unmet needs

Learn how lack of disease control leads to irreversible damage accrual.7

Explore unmet needs
Treatment burden

Learn how current treatments can add substantially to patient burden.5,8

Explore treatment burden

Abbreviations:
AIM, autoimmune myositis.

References:
1. Paik J, et al. Rheumatology. 2025;64:3288–3302;2. Oldroyd AS, et al. Rheumatology (Oxford) 2022;61(5):1760–8;3. Groener M, et al. Front Immunol. 2025;16:1581323; 4. Lundberg IE, et al. Nat Rev Dis Primers. 2021;7(1):86; 5. Aggarwal R, et al. Clin Rheumatol. 2025;44:4169–4178; 6. Oldroyd A, et al. Clin Med (Lond). 2017;17(4):322–328; 7. Janardana R, et al. Mediterr J Rheumatol. 2023 Aug 28;34(4):513-524; 8. Oldroyd, et al. BMC Rheumatol. 2020;4:47.